MM
SUPN icon

MQS Management’s Supernus Pharmaceuticals SUPN Stock Holding History

MQS Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,852
Closed -$327K – 629
2025
Q3 		$327K Sell
6,852
-1,988
-22% -$80.1K 0.19% 230
2025
Q2 		$279K Buy
+8,840
New +$283K 0.15% 288
2023
Q3 		– Sell
-10,595
Closed -$318K – 614
2023
Q2 		$318K Buy
+10,595
New +$371K 0.22% 203

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MQS Management's SUPN Position: Q4 2025 in Review

MQS Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 6,852 shares — an estimated $327K sold.

MQS Management first reported a position in SUPN in Q2 2023 and held it in 3 quarters. The position peaked at $327K in Q3 2025. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

  • MQS Management reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • MQS Management sold 6,852 Supernus Pharmaceuticals shares in Q4 2025, an estimated $327K.
  • MQS Management first reported a position in Supernus Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • MQS Management's Supernus Pharmaceuticals position peaked at $327K in Q3 2025.
  • 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on MQS Management's 13F filing for Q4 2025, filed 9 Feb 2026.